DK1280803T3 - Krystallinsk form II af cabergolin - Google Patents
Krystallinsk form II af cabergolinInfo
- Publication number
- DK1280803T3 DK1280803T3 DK01915373T DK01915373T DK1280803T3 DK 1280803 T3 DK1280803 T3 DK 1280803T3 DK 01915373 T DK01915373 T DK 01915373T DK 01915373 T DK01915373 T DK 01915373T DK 1280803 T3 DK1280803 T3 DK 1280803T3
- Authority
- DK
- Denmark
- Prior art keywords
- cabergoline
- crystalline form
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007307.2A GB0007307D0 (en) | 2000-03-24 | 2000-03-24 | Crystalline form || of cabergoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1280803T3 true DK1280803T3 (da) | 2005-01-24 |
Family
ID=9888432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01915373T DK1280803T3 (da) | 2000-03-24 | 2001-03-19 | Krystallinsk form II af cabergolin |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6673806B2 (pt) |
| EP (1) | EP1280803B1 (pt) |
| JP (1) | JP2003528874A (pt) |
| KR (1) | KR20020081492A (pt) |
| CN (1) | CN1221550C (pt) |
| AR (1) | AR048279A1 (pt) |
| AT (1) | ATE282038T1 (pt) |
| AU (1) | AU783064B2 (pt) |
| BR (1) | BR0109508A (pt) |
| CA (1) | CA2399540A1 (pt) |
| CZ (1) | CZ20023177A3 (pt) |
| DE (1) | DE60107074T2 (pt) |
| DK (1) | DK1280803T3 (pt) |
| EA (1) | EA004376B1 (pt) |
| EE (1) | EE200200544A (pt) |
| ES (1) | ES2231461T3 (pt) |
| GB (1) | GB0007307D0 (pt) |
| HK (1) | HK1052692B (pt) |
| HU (1) | HUP0300389A3 (pt) |
| IL (1) | IL151670A0 (pt) |
| MX (1) | MXPA02009284A (pt) |
| MY (1) | MY126071A (pt) |
| NO (1) | NO20024527D0 (pt) |
| NZ (1) | NZ521314A (pt) |
| PE (1) | PE20011087A1 (pt) |
| PL (1) | PL358252A1 (pt) |
| PT (1) | PT1280803E (pt) |
| SI (1) | SI1280803T1 (pt) |
| SK (1) | SK13572002A3 (pt) |
| WO (1) | WO2001072747A1 (pt) |
| ZA (1) | ZA200207151B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007309D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| GB0007307D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| BR0308304A (pt) * | 2002-03-15 | 2004-12-28 | Pharmacia Corp | Processo para preparar forma i cristalina de cabergolina |
| IL155545A (en) * | 2003-04-21 | 2009-12-24 | Finetech Pharmaceutical Ltd | Solvate form of cabergoline |
| CA2525104A1 (en) | 2003-05-08 | 2004-11-25 | Ivax Pharmaceuticals S.R.O. | Polymorphs of cabergoline |
| GB0409785D0 (en) * | 2004-04-30 | 2004-06-09 | Resolution Chemicals Ltd | Preparation of cabergoline |
| GB0505965D0 (en) | 2005-03-23 | 2005-04-27 | Resolution Chemicals Ltd | Preparation of cabergoline |
| US7339060B2 (en) | 2005-03-23 | 2008-03-04 | Resolution Chemicals, Ltd. | Preparation of cabergoline |
| EP1953157A1 (en) | 2007-01-31 | 2008-08-06 | LEK Pharmaceuticals D.D. | New crystal form of cabergoline |
| US20130163062A1 (en) | 2011-12-22 | 2013-06-27 | Qualcomm Mems Technologies, Inc. | Mechanical smart window with continuously tunable transmission |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US149067A (en) * | 1874-03-31 | Improvement in steam-engine valve-gears | ||
| US144516A (en) * | 1873-11-11 | Improvement in faucets | ||
| US187013A (en) * | 1877-02-06 | Improvement in ovens for gas-stoves | ||
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| GB0007307D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| GB0007309D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| GB0007376D0 (en) | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
-
2000
- 2000-03-24 GB GBGB0007307.2A patent/GB0007307D0/en not_active Ceased
-
2001
- 2001-02-26 PE PE2001000198A patent/PE20011087A1/es not_active Application Discontinuation
- 2001-03-19 ES ES01915373T patent/ES2231461T3/es not_active Expired - Lifetime
- 2001-03-19 EE EEP200200544A patent/EE200200544A/xx unknown
- 2001-03-19 BR BR0109508-0A patent/BR0109508A/pt not_active Application Discontinuation
- 2001-03-19 PT PT01915373T patent/PT1280803E/pt unknown
- 2001-03-19 WO PCT/EP2001/003098 patent/WO2001072747A1/en active IP Right Grant
- 2001-03-19 CN CNB01806471XA patent/CN1221550C/zh not_active Expired - Fee Related
- 2001-03-19 MX MXPA02009284A patent/MXPA02009284A/es active IP Right Grant
- 2001-03-19 JP JP2001570657A patent/JP2003528874A/ja active Pending
- 2001-03-19 EP EP01915373A patent/EP1280803B1/en not_active Expired - Lifetime
- 2001-03-19 CA CA002399540A patent/CA2399540A1/en not_active Withdrawn
- 2001-03-19 EA EA200201017A patent/EA004376B1/ru not_active IP Right Cessation
- 2001-03-19 DE DE60107074T patent/DE60107074T2/de not_active Expired - Fee Related
- 2001-03-19 NZ NZ521314A patent/NZ521314A/en unknown
- 2001-03-19 CZ CZ20023177A patent/CZ20023177A3/cs unknown
- 2001-03-19 KR KR1020027012583A patent/KR20020081492A/ko not_active Application Discontinuation
- 2001-03-19 PL PL01358252A patent/PL358252A1/xx unknown
- 2001-03-19 AR ARP010101262A patent/AR048279A1/es unknown
- 2001-03-19 IL IL15167001A patent/IL151670A0/xx unknown
- 2001-03-19 US US10/239,562 patent/US6673806B2/en not_active Expired - Fee Related
- 2001-03-19 AU AU42482/01A patent/AU783064B2/en not_active Ceased
- 2001-03-19 SI SI200130276T patent/SI1280803T1/xx unknown
- 2001-03-19 HU HU0300389A patent/HUP0300389A3/hu unknown
- 2001-03-19 AT AT01915373T patent/ATE282038T1/de not_active IP Right Cessation
- 2001-03-19 DK DK01915373T patent/DK1280803T3/da active
- 2001-03-19 SK SK1357-2002A patent/SK13572002A3/sk unknown
- 2001-03-22 MY MYPI20011363A patent/MY126071A/en unknown
-
2002
- 2002-09-05 ZA ZA200207151A patent/ZA200207151B/en unknown
- 2002-09-20 NO NO20024527A patent/NO20024527D0/no unknown
-
2003
- 2003-06-27 HK HK03104604.7A patent/HK1052692B/zh not_active IP Right Cessation
- 2003-10-31 US US10/698,664 patent/US6800635B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1169314T3 (da) | Krystallinsk base af citalopram | |
| IS7007A (is) | Kristallaform af asiþrómýsíni | |
| DK1438306T3 (da) | Derivater af UK-2A | |
| DK1307181T3 (da) | Hidtil ukendte sammensætninger af minoxidil | |
| IS3019B (is) | Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi | |
| AR028567A1 (es) | Nuevos derivados de fenil-propargileter | |
| DK1149090T3 (da) | Ny krystallinsk form af kaliumsalt af (S)-omeprazol | |
| IS7103A (is) | Blanda af amínópýrimidínefnasamböndum | |
| AR028596A1 (es) | Nuevos derivados de fenilglicina | |
| DK1107980T3 (da) | Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH | |
| IS5640A (is) | Ný kristalla form af Bensímídazól efnasambandi gegn veirum | |
| DK1280803T3 (da) | Krystallinsk form II af cabergolin | |
| DK1142477T3 (da) | Sammensætninger med reguleret frigivelse | |
| DK1272489T3 (da) | Fremgangsmåde til præparation af cabergolins krystallinske form I | |
| IS6215A (is) | Að mestu leyti kristallað form af melagatrani | |
| PT1322592E (pt) | Derivados substituidos de 1-aminobutan-3-ol | |
| IS5821A (is) | Kristalluð form af ósanetant | |
| IS6127A (is) | Ný kristölluð form af makrólíð sýklalyfi | |
| IS6620A (is) | Nýr fjölgervingur V af tórasemíði | |
| NO20030416D0 (no) | Krystallinsk terapeutisk forbindelse | |
| SE0001187D0 (sv) | Crystalline form | |
| SE0001422D0 (sv) | Crystalline form | |
| DK1282588T3 (da) | Fremstilling af hydroxyforbindelser | |
| DK1191025T3 (da) | Krystaller af lansoprazol | |
| DK1169054T3 (da) | Prognose af PTP LAR-relaterede sygdomme |